L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Selon Oxfam International...l’industrie pharmaceutique empêche des millions de personnes pauvres d’avoir accès aux médicaments, mettant ainsi en péril son propre devenir...Sanofi-Aventis proposait son médicament ...Plavix à un prix 60 fois supérieur à ...[la] version générique indienne du médicament...Pfizer a ainsi intenté un procès au gouvernement des Philippines pour l’usage de clauses de sauvegarde invoquant la santé publique à l’égard du médicament Norvasc...

Zaman çizelgesi

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

12 Şub 2008

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

19 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

18 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

18 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Tarih:

12 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

12 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

12 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

12 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

12 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

12 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

12 Ara 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
Oxfam report "Investing for Life": Company responses

Tarih:

12 Ara 2007

İçerik Türü:

Makale

Mevcut diller: English
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Tarih:

27 Kas 2007

İçerik Türü:

Makale

Mevcut diller: español
Oxfam says top drug companies focusing on patents, not poor

Tarih:

26 Kas 2007

İçerik Türü:

Makale

Mevcut diller: English
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Tarih:

23 Kas 2007

İçerik Türü:

Makale

Mevcut diller: français
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Tarih:

12 Kas 2007

İçerik Türü:

Şirketin Yanıtı

Mevcut diller: English
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices

Tarih:

1 Kas 2007

İçerik Türü:

Makale

Mevcut diller: English

Hikâyenin tümünü gör

Daha fazlasını yükle Daha azını gör

Business & Human Rights
Resource Centre

İş ve & İnsan Hakları Kaynak Merkezi

Bu sayfa Türkçe dilinde mevcut değildir ve şu an French dilinde görüntülenmektedir

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Zaman çizelgesi

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Oxfam report "Investing for Life": Company responses

La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Oxfam says top drug companies focusing on patents, not poor

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices